INT200-Placebo

OTHER2 trials

Sponsors

Intron Biotechnology, Inc.

Conditions

Anti-Bacterial AgentsHealthy VolunteersMethicillin-Resistant Staphylococcus AureusMethicillin-Sensitive Staphylococcus Aureus Infection

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers

CompletedNCT01855048

Intron Biotechnology, Inc.Anti-Bacterial Agents, Healthy Volunteers, Methicillin-Resistant Staphylococcus Aureus

Start: 2013-08-06End: 2014-02-07Updated: 2021-11-03

A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers

CompletedNCT03446053

Intron Biotechnology, Inc.Anti-Bacterial Agents, Healthy Volunteers, Methicillin-Resistant Staphylococcus Aureus +1

Start: 2018-02-07End: 2019-02-07Updated: 2021-11-03

Related Papers

A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.

2022-01-1014 citations

Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers

Antimicrobial Agents and Chemotherapy2017-03-28173 citations